Case No. 07-CV-2536 PSG (PLAx)
Welcome to the Information Website for the
In re Amgen Inc. Securities Litigation.
Court-appointed Class Representative on behalf of itself and the Class (defined below), have reached a proposed settlement of the Action for $95 million USD (the “Settlement”) that, if approved, will resolve all claims in the Action.
If you purchased the publicly traded securities of Amgen, Inc. (“Amgen”) during the period from April 22, 2004 through and including May 10, 2007, you may have important legal rights.
Beginning in April 2007, several putative securities fraud class actions were filed against Defendants in the United States District Court for the Central District of California. In July 2007, the Court entered an Order consolidating the securities class actions and appointing Connecticut Retirement Plans and Trust Funds as lead plaintiff pursuant to the Private Securities Litigation Reform Act of 1995. The Class was certified on August 12, 2009, and Connecticut Retirement was appointed Class Representative. In the operative Amended Complaint filed on April 22, 2014, Class Representative alleges, among other things, that Amgen and the Individual Defendants misled and defrauded investors concerning the safety, marketing, and market demand of two of the Amgen’s flagship products, Aranesp® (darbepoetin alfa) and Epogen® (epoetin alfa), allegedly in violation of the federal securities laws. More detailed information on the case background can be found under the FAQs or in the Notice.
The Frequently Asked Questions page of this website has more information on your rights as a Class Member in this Action.